

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: David A. Griffith

Examiner: To Be Assigned

APPLICATION NO.: To Be Assigned

FILING DATE: To Be Assigned :Group Art Unit: To Be Assigned

TITLE: Cannabinoid Receptor Ligands and Uses Thereof :

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: January 21, 2004

Arlene K. Musser  
Arlene K. Musser  
Attorney for Applicant(s)  
Reg. No. 37,895

Pfizer Inc.  
Patent Department, Box 8260-1611  
Eastern Point Road  
Groton, CT 06340  
(860) 715-0871

EXPRESS MAIL NO. EV 271824831US

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. PC25512A		SERIAL NO. To Assigned		
		APPLICANT DAVID A. GRIFFITH				
		FILING DATE Herewith		GROUP To Assigned		

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
M	US 3,865,824	02/11/75	Kobe, et al.			
M	US 3,910,907	10/07/75	O'Brien, et al.			
M	US 3,995,039	11/30/76	Rooney, et al.			
M	US 4,183,930	01/15/80	Cohen			
M	US 4,734,414	03/29/88	Kim			
M	US 4,767,858	08/30/88	Kim			
M	US 4,824,834	04/25/89	Fujii, et al.			
M	US 4,992,442	02/12/91	Tsujitani, et al.			
M	US 5,055,479	10/08/91	Takiguchi, et al.			
M	US 5,086,057	02/04/92	Takiguchi, et al.			
M	US 5,137,887	08/11/92	Hashimoto, et al.			
M	US 5,246,932	09/21/93	Caulkett, et al.			
M	US 5,270,311	12/14/93	Caulkett, et al.			
M	US 5,290,776	03/01/94	Caulkett, et al.			
M	US 5,356,894	10/18/94	Rodney, et al.			
M	US 5,380,714	01/10/95	Jones, et al.			
M	US 5,420,128	05/30/95	Kiyokawa, et al.			
M	US 5,571,813	11/05/96	Ruhter, et al.			
M	US 5,602,136	02/11/97	Ruhter, et al.			
M	US 5,602,137	02/11/97	Ruhter, et al.			
M	US 6,060,478	05/09/00	Gilligan, et al.			
M	US 6,124,289	09/26/00	He, et al.			


EXPRESS MAIL NO. EZV29182483145

INFORMATION DISCLOSURE CITATION LIST.DOT, 9/99

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. PC25512A		SERIAL NO. To Be Assigned			
		APPLICANT DAVID A. GRIFFITH					
		FILING DATE Herewith		GROUP To Be Assigned			
<i>M</i> <i>M</i> <i>M</i> <i>M</i> <i>M</i> <i>M</i> <i>M</i> <i>M</i> <i>M</i> <i>M</i>	US 6,136,809	10/24/00	Gilligan, et al.				
	US 6,191,131 B1	02/20/01	He, et al.				
	US 6,194,410 B1	02/27/01	Bos, et al.				
	US 6,313,124 B1	11/06/01	He, et al.				
	US 6,358,950 B1	03/19/02	He, et al.				
	US 6,372,743 B1	04/16/02	Darrow, et al.				
	US 6,476,038 B1	11/05/02	Darrow, et al.				
	US 6,509,338 B1	01/21/03	Olson, et al.				
	US 2003/0008885 A1	01/09/03	He, et al.				
	US 2003/0125330 A1	07/03/03	Gilligan				
FOREIGN PATENT DOCUMENTS							
DOCUMENT NUMBER			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES
<i>M</i> <i>M</i>	EP 269 859 B2	10/18/95	Europe				
	WO 01/54695 A1	08/02/03	PCT				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
<i>M</i> <i>M</i> <i>M</i> <i>M</i> <i>M</i>	Sato, Yasunobu, et al., "Studies on Cardiovascular Agents. 6. Synthesis and Coronary Vasodilating and Antihypertensive Activities of 1,2,4-Triazolo[1,5-a]pyrimidines Fused to Heterocyclic Systems," <i>J. Med. Chem.</i> , <b>23</b> , 927-937 (1980).						
	Senga, Keitaro, et al., "Synthesis and Antischistosomal Activity of Certain Pyrazolo[1,5-a]pyrimidines," <i>J. Med Chem.</i> , <b>24</b> , 610-613 (1981).						
	Senga, Keitaro, et al., "Synthesis and Enzymic Activity of Various Substituted Pyrazolo[1,5-a]-1,3,5-triazines as Adenosine Cyclic 3',5'-Phosphate Phosphodiesterase Inhibitors," <i>J. Med. Chem.</i> , <b>25</b> , 243-249 (1982).						
	He, Liqi, et al., "4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)-pyrazolo[1,5-a]-1,3,5-triazine: A Potent, Orally bioavailable CRF3 Receptor Antagonist," <i>J. Med. Chem.</i> , <b>43</b> , 449-456 (2000).						
	Almansa, Carmen, et al., "Synthesis and SAR of a New Series of COX-2 Selective Inhibitors: Pyrazolo[1,5-a]pyrimidines," <i>J. Med. Chem.</i> , <b>44</b> , 350-361 (2001).						
EXAMINER	<i>V. Balasubramanian</i>			DATE CONSIDERED	9/16/05		

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 14<sup>th</sup> day of March, 2004.

By

  
(Signature of person mailing)

Tracy Mycroft

(Typed or printed name of person)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**IN RE APPLICATION OF: David A. Griffith :**

**APPLICATION NO.: 10/763,105 : Examiner: To be assigned**

**FILING DATE: January 21, 2004 : Group Art Unit: To be assigned**

**TITLE: Cannabinoid Receptor Ligands and Uses Thereof :**

Hon. Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.**

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.


The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Date: March 11, 2004

Respectfully submitted,

  
Arlene K. Musser  
Attorney for Applicant(s)  
Reg. No. 37,895


Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 715-0871



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			ATTY. DOCKET NO. PC25512A			SERIAL NO. 10/763,105						
			APPLICANT David A. Griffith									
			FILING DATE January 21, 2004			GROUP Unknown						
<b>U.S. PATENT DOCUMENTS</b>												
EXAMINER INITIAL		DOCUMENT NUMBER				DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)		
<b>FOREIGN PATENT DOCUMENTS</b>									TRANSLATION			
			DOCUMENT NUMBER				DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>												
M			C. Bellec et al., Can. J. Chem., 1981, Vol. 59, pp 2826-2832, "Deaminative Electrochemical Reduction of pyrazolo[1,5-a]pyrimidine-7-amines".									
M			A. Takamizawa et al., Chem. Pharm. Bull., 1965, Vol. 13, 10, pp 1207-1220, "Syntheses of Pyrazole Derivatives. XI." <sup>1</sup> Acetylation Products of 7-Aminopyrazolo[1,5-a]pyrimidines. Supplement".									
M			Y. Sawaki et al., Bull. Chem. Soc. Jpn., 1981, Vol. 54, pp 793-799, "Mechanism of the Reaction of Nitriles with Alkaline Hydrogen Peroxide. Reactivity of Peroxycarboximic Acid and Application to Superoxide Ion Reaction".									
M			H. Beyer et al., 1960, pp 2209-2216, ' Zur Umsetzung von Ketonitrilen mit Hydrazinderivaten der Kohlensäure'									
M			J. Kobe et al., December 1974, Vol. 11, pp 991-996, "The Chemistry of 4-Hydrazino-7-phenylpyrazolo[1,5-a]-1,3,5-triazines".									
EXAMINER	V. Balasubramanian						DATE CONSIDERED	9/16/05				
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.												

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 28<sup>th</sup> day of May, 2004.

By

  
(Signature of person mailing)

Tracy Mycroft

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: David A. Griffith

APPLICATION NO.: 10/763,105 : Examiner: To be Assigned

FILING DATE: January 21, 2004 : Group Art Unit: To be Assigned

TITLE: Cannabinoid Receptor Ligands and Uses Thereof :

Hon. Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

A first Office Action on the merits has not been received; therefore, no fee for this Supplemental Information Disclosure Statement is required. In the event that an Office Action has been mailed, please charge the appropriate fee to Deposit Account No. 16-1445.


The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Respectfully submitted,

Date: May 28, 2004

Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 715-0871

  
Arlene K. Musser  
Attorney for Applicant(s)  
Reg. No. 37,895

JUN 01 2004  
12:00 PM  
U.S. PATENT AND TRADEMARK OFFICE  
EXAMINER: [Signature]

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. PC25512A		SERIAL NO. 10/763,105		
		APPLICANT DAVID A. GRIFFITH				
		FILING DATE 1/21/04		GROUP Not Available		
<b>U.S. PATENT DOCUMENTS</b>						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
W	US 20010027193 A1	10/04/01	Achard, et al.			
M	US 20010053788 A1	12/20/01	Lange, et al.			
M	US 20020019383 A1	02/14/02	Achard, et al.			
M	US 20020019421 A1	02/14/02	Biberman, et al.			
M	US 20020035102 A1	03/21/02	Achard, et al.			
M	US 20020091114 A1	07/11/02	Plot-Grosjean, et al.			
M	US 20020119972 A1	08/29/02	Leftheris, et al.			
M	US 20020128302 A1	09/12/02	Maruani, et al.			
M	US 20020188007 A1	12/12/02	Barth, et al.			
M	US 20030003145 A1	01/02/03	Abramovici, et al.			
M	US 20030055033 A1	03/20/03	Achard, et al.			
M	US 20030114495 A1	06/19/03	Finke, et al.			
M	US 20030139386 A1	07/24/03	Cote, et al.			
M	US 20030199536 A1	10/23/03	Thomas, et al.			
M	US 20040077650 A1	4/22/04	Dow			
M	US 20040092520 A1	5/12/04	Griffith			
M	US 4,925,846	05/15/90	Deacon, et al.			
M	US 4,944,790	07/31/90	Moser, et al.			
M	US 5,134,142	07/28/92	Matsuo, et al.			
M	US 5,462,960	10/31/95	Barth, et al.			
M	US 5,596,106	01/21/97	Cullinan, et al.			
M	US 5,624,941	04/29/97	Barth, et al.			
M	US 5,744,491	04/28/98	Boigegrain, et al.			

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. PC25512A		SERIAL NO. 10/763,105			
		APPLICANT DAVID A. GRIFFITH					
		FILING DATE 1/21/04		GROUP	Not Available		
IM	US 5,744,493	04/28/98	Boigegrain, et al.				
IM	US 5,747,524	05/05/98	Cullinan, et al.				
IM	US 5,925,768	07/20/99	Barth, et al.				
CM	US 6,028,084	02/22/00	Barth, et al.				
IM	US 6,100,259	08/08/00	Xiang, et al.				
IM	US 6,344,474 B1	02/05/02	Maruani, et al.				
IM	US 6,355,631 B1	03/12/02	Bouchard, et al.				
IM	US 6,432,984 B1	08/13/02	Barth, et al.				
IM	US 6,476,060 B2	11/05/02	Lange, et al.				
IM	US 6,479,479 B2	11/12/02	Achard, et al.				
IM	US 6,509,367 B1	01/21/03	Martin, et al.				
IM	US 6,518,264 B2	02/11/03	Achard, et al.				
IM	US 6,566,356 B2	05/20/03	Achard, et al.				
<b>FOREIGN PATENT DOCUMENTS</b>							
DOCUMENT NUMBER		DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
✓	CA 2,387,138 equiv. to WO 01/028557 A1	04/26/01	CA				
✓	US 2003087933 equiv. to WO 01/58450 A2	08/16/01	PCT				
✓	US 5051518 equiv. to EP 293,220 B1	8/31/94	EP				
✓	US 6642258 equiv. to WO 01/24798 A1	04/12/01	PCT				
✓	WO 00/15609 A1	05/23/00	PCT				X
✓	WO 01/029007 A1	04/26/01	PCT				
✓	WO 01/032629 A1	05/10/01	PCT				X
✓	WO 01/032663 A2	05/10/01	PCT				X
✓	WO 01/85092 A2	11/15/01	PCT				X
✓	WO 02/076949 A1	10/03/02	PCT				

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. PC25512A		SERIAL NO. 10/763,105	
		APPLICANT DAVID A. GRIFFITH			
		FILING DATE 1/21/04		GROUP	Not Available
W	WO 03/006007 A1	01/23/03	PCT		
W	WO 03/007887 A2	01/30/03	PCT		
W	WO 03/018060 A1	03/06/03	PCT		X
W	WO 03/020217 A2	03/13/03	PCT		
W	WO 03/020314 A1	03/13/03	PCT		X
W	WO 03/026647 A1	04/03/03	PCT		
W	WO 03/026648 A1	04/03/03	PCT		
W	WO 03/027069 A1	04/03/03	PCT		
W	WO 03/027076 A2	04/03/03	PCT		
W	WO 03/027114 A1	04/03/03	PCT		
W	WO 03/040107 A1	05/15/03	PCT		
W	WO 03/051850 A1	06/26/03	PCT		
W	WO 03/051851 A1	06/26/03	PCT		
W	WO 03/075660 A1	09/18/03	PCT		
W	WO 03/077847 A2	09/25/03	PCT		
W	WO 03/078413 A1	09/25/03	PCT		
W	WO 03/082190 A2	10/09/03	PCT		
W	WO 03/082191 A2	10/09/03	PCT		
W	WO 03/082256 A2	10/09/03	PCT		X
W	WO 03/082833 A1	10/09/03	PCT		X
W	WO 03/084943 A2	10/16/03	PCT		X
W	WO 03/086288 A2	10/23/03	PCT		
W	WO 03/087037 A1	10/23/03	PCT		
W	WO 04/012617 A2	02/12/04	PCT		
W	WO 96/02248 A1	02/01/96	PCT		

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. PC25512A	SERIAL NO. 10/763,105
		APPLICANT DAVID A. GRIFFITH	
		FILING DATE 1/21/04	GROUP Not Available
OTHER DOCUMENTS ( <i>Including Author, Title, Date, Pertinent Pages, Etc.</i> )			
W	✓	Tzavara, E.T., et al., "The CB1 Receptor Antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: Implications for Therapeutic Actions," <i>J Pharmacol</i> , <b>138</b> , 544-553 (2003).	
W	✓	Racz, I., et al., "A Critical Role for the Cannabinoid CB1 Receptors in Alcohol Dependence and Stress-Stimulated Ethanol Drinking," <i>J Neurosci</i> , <b>23</b> (6), 2453-2458 (2003).	
W	✓	Croci, T., et al., "Role of Cannabinoid CB1 Receptors and Tumor Necrosis Factor- $\alpha$ in the gut and systemic anti-inflammatory activity of SR 141716 (Rimonabant) in rodents," <i>Brit J Pharmacol</i> , <b>140</b> , 115-122 (2003).	
W	✓	DaSilva, G.E., et al., "Potentiation of Penile Erection and Yawning Responses to Apomorphine by Cannabinoid Receptor Antagonists in Rats," <i>Neurosci Let</i> , <b>349</b> , 49-52 (2003).	
W	✓	Wang, L., et al., "Endocannabinoid Signaling via Cannabinoid Receptor 1 is Involved in Ethanol Preference and its Age-Dependent Decline in Mice," <i>PNAS</i> , <b>100</b> (3), 1393-1398 (2003).	
W	✓	Ruiu, S., et al., "Synthesis and Characterization of NESS 0327: A Novel Putative Antagonist of the CB1 Cannabinoid Receptor," <i>J Pharmacol Exp Therap</i> , <b>306</b> , 363-370 (2003).	
W	✓	Howlett, A.C., et al., "International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors," <i>Pharmacol Rev</i> , <b>54</b> , 161-202 (2002).	
W	✓	Gomez, R., et al., "A Peripheral Mechanism for CB1 Cannabinoid Receptor-Dependent Modulation of Feeding," <i>J. Neurosci</i> , <b>22</b> (21), 9612-9617 (2002).	
W	✓	Wiley, J.L., et al., "Novel Pyrazole Cannabinoids: Insights into CB1 Receptor Recognition and Activation," <i>J Pharmacol Exp Therap</i> , <b>296</b> (3), 1013-1022 (2001).	
W	✓	Lellemand, F., et al., "Effects of CB1 Cannabinoid Receptor Blockade on Ethanol Preference After Chronic Ethanol Administration," <i>Alcohol Clin Exp Res</i> , <b>25</b> (9), 1317-1323 (2001).	
W	✓	Pertwee, R.G., "Cannabinoids and the Gastrointestinal Tract," <i>Gut</i> , <b>48</b> , 859-867 (2001).	
W	✓	Pertwee, R.G., "Cannabinoid Receptor Ligands: Clinical and Neuropharmacological Considerations, Relevant to Future Drug Discovery and Development," <i>Exp. Opin. Invest. Drugs</i> , <b>9</b> (7), 1573-1571 (2000).	
W	✓	Hungund, B.L and B.S. Basavarajappa, "Are Anandamide and Cannabinoid Receptors involved in Ethanol Tolerance? A Review of the Evidence," <i>Alcohol &amp; Alcoholism</i> , <b>35</b> (2) 126-133, (2000).	
W	✓	Freedland, C.S., et al., "Effects of SR141716A, a Central Cannabinoid Receptor Antagonist, on Food-maintained Responding," <i>Pharmacol Biochem Behav</i> , <b>67</b> , 265-270 (2000).	
W	✓	Lin, R., et al., "Structure-Activity Relationships of Pyrazole Derivatives as Cannabinoid Receptor Antagonists" <i>J. Med. Chem</i> , <b>42</b> , 769-776 (1999).	
W	✓	Pertwee, R.G., "Pharmacology of Cannabinoid Receptor Ligands" <i>Curr Med Chem</i> , <b>6</b> , 635-664 (1999).	
W	✓	Basavarajappa, B.S., et al., "Chronic Ethanol Administration Down-regulates Cannabinoid Receptors in Mouse Brain Synaptic Plasma Membrane," <i>Brain Res</i> , <b>793</b> , 212-218 (1998).	
W	✓	Thomas, B.F., et al., "Comparative Receptor Binding Analyses of Cannabinoid Agonists and Antagonists," <i>J Pharmacol Exp Therap</i> , <b>285</b> , 285-292 (1998).	
W	✓	Colombo, G., et al., "Appetite Suppression and Weight Loss after the Cannabinoid Antagonist SR141716," <i>Life Sci</i> , <b>63</b> , PL113-PL117 (1998);	
W	✓	Simiand, J., et al., "SR141716, a CB1 Cannabinoid Receptor Antagonist, Selectively Reduces Sweet Food Intake in Marmoset," <i>Behav. Pharmacol</i> , <b>9</b> , 179-181 (1998).	
W	✓	Chaperon, F., et al., "Involvement of Central Cannabinoid (CB1) Receptors in the Establishment of Place Conditioning in Rats," <i>Psychopharmacology</i> , <b>135</b> , 324-332 (1998).	
W	✓	Arnone, M., et al., "Selective Inhibition of Sucrose and Ethanol Intake by SR141716, an Antagonist of Central Cannabinoid (CB1) Receptors," <i>Psychopharmacol</i> , <b>132</b> , 104-106 (1997).	

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			ATTY. DOCKET NO. PC25512A	SERIAL NO. 10/763,105
			APPLICANT DAVID A. GRIFFITH	
			FILING DATE 1/21/04	GROUP Not Available
M		Savontaus, E., et al., "Anti-Obesity Effect of MPV-1743 A III, a Novel Imidazoline Derivative, in Genetic Obesity," <u>Eur J Pharmacol</u> , <b>328</b> , 207-215 (1997).		
M		Sanudo-Pena, M.C., et al., "Endogenous Cannabinoids as an Aversive or Counter-rewarding System in the Rat," <u>Neurosci Let</u> , <b>223</b> , 125-128 (1997).		
M		Gifford, A.N., et al., "Electrically Evoked Acetylcholine Release from Hippocampal Slices is Inhibited by the Cannabinoid Receptor Agonist, WIN 55212-2 and is Potentiated by the Cannabinoid Antagonist, SR 141716A," <u>J Pharmacol Exp Ther</u> , <b>277</b> , 1431-1436 (1996).		
M		Compton, D.R., et al., "In Vivo Characterization of a Specific Cannabinoid Receptor Antagonist (SR141716A); Inhibition of Delta-9-Tetrahydrocannabinol-Induced Responses and Apparent Agonist Activity," <u>J Pharmacol Exp Ther</u> , <b>277</b> , 586-594 (1996).		
M		Mansbach, R.S., et al., "Effects of the Cannabinoid CB1 Receptor Antagonist SR141716A on the Behavior of Pigeons and Rats," <u>Psychopharmacology</u> , <b>124</b> , 315-322 (1996).		
M		Lichtman, A.H., et al., "Delta-9-Tetrahydrocannabinol Impairs Spatial Memory through a Cannabinoid Receptor Mechanism," <u>Psychopharmacology</u> , <b>126</b> , 125-131 (1996).		
M		Perio, A., et al., "Central Mediation of the Cannabinoid Cue: Activity of a Selective CB1 Antagonist, SR141716A," <u>Behavioral Pharmacology</u> , <b>7</b> , 65-71 (1996).		
M		Rinaldi-Carmona, M., et al., "Biochemical and Pharmacological Characterization of SR141716A, The First Potent and Selective Brain Cannabinoid Receptor Antagonist," <u>Life Sci</u> , <b>56</b> , 1941-1947 (1995).		
M		Pertwee, R., et al., "AM630, A Competitive Cannabinoid Receptor Antagonist," <u>Life Sci</u> , <b>56</b> , 1949-1955 (1995).		
M		Rinaldi-Carmona, M., et al., "SR141716A, a Patent and Selective Antagonist of the Brain Cannabinoid Receptor," <u>FEBS Letters</u> , <b>350</b> , 240-244 (1994).		
M		Dutta, A., et al., "The Synthesis and Pharmacological Evaluation of the Cannabinoid Antagonist SR 141716A," <u>Med. Chem. Rev.</u> <b>5</b> , 54-62 (1994).		
M		Drummond, J., et al., "Evaluation and Synthesis of Aminohydroxyisoxazoles and Pyrazoles as Potential Glycine Agonists," <u>J. Med. Chem.</u> , <b>32</b> , 2116-2128 (1989).		
M		Murray, W., et al., "A Simple Regioselective Synthesis of Ethyl 1,5-Diarylpyrazole-3-carboxylates" <u>J. Heterocyclic Chem</u> , <b>26</b> , 1389 (1989).		
H		Dewey, W.L. "Cannabinoid Pharmacology," <u>Pharmacological Reviews</u> , <b>38</b> (2)m 151-178 (1986).		
H		Tewari, R.S., et al., "1,3-Dipolar Cycloaddition and Nucleophilic Substitution Reactions of C-Acetyl and C-Ethoxycarbonyl Derivative of Hydrazidoyl Bromides" <u>Tetrahedron</u> , <b>39</b> (1) 129-136 (1983).		
M		Birkofe, L. and K. Richtzenhain, "Silyl-Derivate von Pyrazol, Isoxazol und 1,2,3-Triazol" <u>Chem. Ber.</u> <b>112</b> , 2829-2836 (1979).		
M		Franke, H. et al., "Polare Cycloadditionen von elektronenreichen Mehrfach-bindungssystemen an 1,3,4-oxadiazolium-Salze: Synthese von 3aH-[1,3,4]Oxadiazolo[3,2-a]chinolinen" <u>Chem. Ber.</u> <b>112</b> , 3623-3636 (1979).		
M		Sucrow, W., et al., "Bimolekulare Cyclisierung von 2-(1-Methylhydrazino)maleinsäure-dimethylester" <u>Chem. Ber.</u> <b>112</b> , 1712-1718 (1979).		
EXAMINER		DATE CONSIDERED		9/16/08
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				



IFW

Patent Application  
Attorney Docket No. PC25512A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 27<sup>th</sup> day of July, 2004.

By \_\_\_\_\_

*T. Mycroft*  
(Signature of person mailing)  
Tracy Mycroft

\_\_\_\_\_  
(Typed or printed name of person)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**IN RE APPLICATION OF: David A. Griffith**

**APPLICATION NO.: 10/763,105**

**Examiner: To be Assigned**

**FILING DATE: January 21, 2004**

**Group Art Unit: 1614**

**TITLE: Cannabinoid Receptor Ligands and Uses Thereof**

Hon. Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

A first Office Action on the merits has not been received; therefore, no fee for this Supplemental Information Disclosure Statement is required. In the event that an Office Action has been mailed, please charge the appropriate fee to Deposit Account No. 16-1445.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Respectfully submitted,

Date: July 27, 2004

Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 715-0871

*Arlene K. Musser*


Arlene K. Musser  
Attorney for Applicant(s)  
Reg. No. 37,895

(Use several sheets if necessary)									APPLICANT David A. Griffith					
FILING DATE January 21, 2004									GROUP 1614					
<b>U.S. PATENT DOCUMENTS</b>														
EXAMINER INITIAL	DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FLING DATE (IF APPROPRIATE)	
<b>FOREIGN PATENT DOCUMENTS</b>														
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
W	WO	03	0	9	5	4	5	5	11/20/03	International	C07D			
W	EP	1	3	5	4	8	8	4	10/22/03	European	C07D			
M	WO	02	0	5	3	5	6	5	7/11/02	International	C07D			X
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>														
			U.S. Patent Application Publication No. 2004/0072833, published April 15, 2004, equivalent to WO02053565.											
EXAMINER			V. Balasubramaniam						DATE CONSIDERED			9/16/08		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

Conforms with FORM PTO-FB-A820

#### INFORMATION DISCLOSURE

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




FW

Patent Application  
Attorney Docket No. PC25512A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 13<sup>rd</sup> day of December, 2004.

By \_\_\_\_\_

  
(Signature of person mailing)

Erica L. Smith

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: David A. Griffith

:

APPLICATION NO.: 10/763,105

: Examiner: To be Assigned

FILING DATE: January 21, 2004

: Group Art Unit: 1614

TITLE: Cannabinoid Receptor Ligands and Uses Thereof

Hon. Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

A first Office Action on the merits has not been received; therefore, no fee for this Supplemental Information Disclosure Statement is required. In the event that an Office Action has been mailed, please charge the appropriate fee to Deposit Account No. 16-1445.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).


Respectfully submitted,

Date: 12/13/04



Arlene K. Musser  
Attorney for Applicant(s)  
Reg. No. 37,895


Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 715-0871



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			ATTY. DOCKET NO. PC25512A		SERIAL NO. 10/763,105			
			APPLICANT David A. Griffith					
			FILING DATE January 21, 2004		GROUP 1614			
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)	
W		2004/0077650	4/22/04	Dow	514	242		
W		2004/0092520	5/13/04	Griffith	514	242		
W		2004/0122074	6/24/04	Dow, et al.	514	397		
FOREIGN PATENT DOCUMENTS								
DOCUMENT NUMBER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
								YES
								NO
EXAMINER				DATE CONSIDERED		9/16/05		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE



Patent Application  
Attorney Docket No. PC25512A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 27 day of January, 2005.

By Erica L. Smith

(Signature of person mailing)

Erica L. Smith

(Typed or printed name of person)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**IN RE APPLICATION OF: David A. Griffith**

**APPLICATION NO.: 10/763,105** : **Examiner: To be Assigned**

**FILING DATE: January 21, 2004** : **Group Art Unit: 1614**

**TITLE: Cannabinoid Receptor Ligands and Uses Thereof** :

Hon. Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

Under 37 C.F.R. 1.97(e)(1), I hereby certify that each item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this statement.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

The Examiner is respectfully requested to indicate his or her consideration of the foregoing items by initialing, signing, and dating the accompanying PTO-FB-A820 and then returning a copy of the same to the undersigned. It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: January 24, 2005  
Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 715-0871

Arlene K. Musser  
Arlene K. Musser  
Attorney for Applicant(s)  
Reg. No. 37,895

(Use several sheets if necessary)		APPLICANT David A. Griffith											
		FILING DATE January 21, 2004				GROUP 1614							
<b>U.S. PATENT DOCUMENTS</b>													
EXAMINER INITIAL	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<b>FOREIGN PATENT DOCUMENTS</b>													
EXAMINER INITIAL	DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
VM	WO	02	0	7	2	2	0	2	3/6/02	International	A61P	25/00	
VM	WO	03	0	7	6	4	4	1	2/24/03	International	C07D	487/04	
VM	WO	2004	0	2	2	0	5	4	9/5/03	International	A61K	31/415	
VM	WO	9	8	0	3	5	1	0	7/23/97	International	C07D	487/04	
EXAMINER	V. Balasubramanian							DATE CONSIDERED	9/16/08				
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE